Following Industry, OPDP Hopes to Eliminate Silos in Ad Review
March 7th 2013The Office of Prescription Drug Promotion (OPDP) is reorganizing its two primary advertising review divisions – professional and consumer – in an attempt to stay in line with the silo-breaking, multi-channel promotional output pouring in from pharma.
Part D Politics: Medicare Drug Rebates or Price Controls?
February 19th 2013While health care was barely mentioned in the recent State of the Union address, President Obama generated some interest in his proposal to cut Medicare spending by reducing “taxpayer subsidies to prescription drug companies.”
US Cuts Could Jeopardize Global Health Innovations, Says Report
February 19th 2013Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
The Sunshine Act: Cloudier Still?
February 6th 2013With the recent release of the Patient Protection Sunshine Act (PPSA), the Center for Medicare and Medicaid Services (CMS) has established reporting requirements to ensure that drug manufacturers properly disclose payments to physicians in areas of research, continuing medical education, etc.
Five Compliance Questions to Ask Yourself, from the DOJ
January 30th 2013At CBI’s 10th Annual Pharmaceutical Compliance Congress, Maame Ewusi-Mensah Frimpong, deputy assistant attorney general, consumer protection branch, civil division, at the US Department of Justice, said being compliant means understanding people, and their motivations.